NCT05613738View on ClinicalTrials.gov

177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer

NARecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 23, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

November 15, 2025

Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
DRUG

1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01

All patients were intravenous injected with single dose 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.

DRUG

1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01

All patients were intravenous injected with single dose 1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.

DRUG

2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01

All patients were intravenous injected with single dose 2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER